GlassScriptPhysician profile
Rhonda Brown
NPI 1881934842
$1,427.63
in general payments reported to CMS, 2019-2025
21 companies · $578 in 2025
The $578 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.34 · 2022: $146 · 2023: $378 · 2024: $289 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.84 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $288.16 | 2022-2024 | |
| Lilly USA, LLC | $205.81 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $202.93 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $145.80 | 2022-2025 | Ozempic |
| Amgen INC. | $122.45 | 2022-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $56.55 | 2024-2025 | Optis, Dragonfly Opstar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.12 | 2025 | Jardiance |
| Astellas Pharma US INC | $47.96 | 2024-2025 | Veozah |
| Corcept Therapeutics | $42.81 | 2025 | Korlym |
| Exact Sciences Corporation | $38.76 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.55 | 2022-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $26.40 | 2022 | |
| Lundbeck LLC | $25.15 | 2023 | Rexulti |
| Ars Pharmaceuticals Operations, INC. | $23.58 | 2025 | Neffy |
| Ironwood Pharmaceuticals, INC | $22.92 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $20.18 | 2023 | Seglentis |
| Ultragenyx Pharmaceutical INC. | $18.81 | 2025 | Dojolvi |
| Pfizer INC. | $15.21 | 2024 | |
| Qiagen, LLC | $14.09 | 2025 | |
| Radius Health, INC. | $13.42 | 2021 | |
| Depuy Synthes Sales INC. | $12.97 | 2023 | Orthovisc, Monovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.